de Bie Rob M A, Katzenschlager Regina, Swinnen Bart E K S, Peball Marina, Lim Shen-Yang, Mestre Tiago A, Perez Lloret Santiago, Coelho Miguel, Aquino Camila, Tan Ai Huey, Bruno Veronica, Dijk Joke M, Heim Beatrice, Lin Chin-Hsien, Kauppila Linda Azevedo, Litvan Irene, Spijker René, Seppi Klaus, Costa João, Sampaio Cristina, Fox Susan H, Silverdale Monty A
Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Klinik Donaustadt, Vienna, Austria.
Mov Disord. 2025 May;40(5):776-794. doi: 10.1002/mds.30162. Epub 2025 Mar 8.
To update evidence-based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD).
The International Parkinson and Movement Disorder Society (MDS) Evidence Based Medicine in Movement Disorders Committee recommendations for the treatments of PD were first published in 2002 and regularly updated. The current review uses a new methodology, including the Cochrane Risk of Bias tool and a modified version of GRADE (Grading of Recommendations, Assessment, Development, and Evaluations).
On January 1, 2023, a literature search was conducted without date limit in the MEDLINE, Embase, and Cochrane databases using the following search terms: Parkinson disease, levodopa and, for the Embase database, randomized controlled trial (RCT). The inclusion criteria for studies were: patients with PD, on oral levodopa therapy, experiencing motor fluctuations, investigating an intervention that was (commercially) available in at least one country, study design RCT, and with a follow-up duration of at least 3 months.
A total of 102 studies were included. Levodopa extended release, pramipexole immediate release and extended release, ropinirole immediate release, rotigotine, opicapone, safinamide, and bilateral subthalamic nucleus deep brain stimulation (DBS) were assessed as efficacious, and continuous intestinal levodopa infusion, continuous subcutaneous levodopa, continuous subcutaneous apomorphine, ropinirole prolonged release, ropinirole patch, entacapone, rasagiline, istradefylline, amantadine extended release, zonisamide, bilateral globus pallidus DBS, and pallidotomy were assessed as likely efficacious for the treatment of motor fluctuations in people with PD who are already being treated with levodopa.
There are several treatment options that can improve motor fluctuations in PD. These recommendations will assist physicians and patients in determining which intervention to use. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
更新治疗帕金森病(PD)运动波动的循证医学建议。
国际帕金森和运动障碍协会(MDS)运动障碍循证医学委员会关于PD治疗的建议于2002年首次发布,并定期更新。当前综述采用了新方法,包括Cochrane偏倚风险工具和改良版GRADE(推荐分级、评估、制定与评价)。
2023年1月1日,在MEDLINE、Embase和Cochrane数据库中进行无日期限制的文献检索,检索词如下:帕金森病、左旋多巴,对于Embase数据库,还包括随机对照试验(RCT)。研究的纳入标准为:PD患者、接受口服左旋多巴治疗、出现运动波动、研究至少在一个国家有(商业)可用的干预措施、研究设计为RCT且随访期至少3个月。
共纳入102项研究。左旋多巴缓释剂、普拉克索速释剂和缓释剂、罗匹尼罗速释剂、罗替戈汀、奥匹卡朋、沙芬酰胺以及双侧丘脑底核深部脑刺激(DBS)被评估为有效,持续肠道左旋多巴输注、持续皮下左旋多巴、持续皮下阿扑吗啡、罗匹尼罗长效释放剂、罗匹尼罗贴片、恩他卡朋、雷沙吉兰、艾司他卡林、金刚烷胺缓释剂、唑尼沙胺、双侧苍白球DBS以及苍白球毁损术被评估为对已接受左旋多巴治疗的PD患者的运动波动治疗可能有效。
有多种治疗方案可改善PD的运动波动。这些建议将帮助医生和患者确定使用哪种干预措施。© 2025作者。《运动障碍》由Wiley Periodicals LLC代表国际帕金森和运动障碍协会出版。